Physician profile
Rispba N Mccray-Garrison
NPI 1164613352
$69,769.23
in general payments reported to CMS, 2019-2025
6 companies · $30K in 2025
The $30K reported for 2025 was more than what 99% of General Practice providers received nationally (typical 2025 total: $105).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $722 · 2022: $7,725 · 2023: $21K · 2024: $11K · 2025: $30K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $61K · Food and Beverage: $22.61.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $61,300.00 |
| Food and Beverage | $22.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $68,775.00 | 2022-2025 | |
| Merz North America, INC. | $687.63 | 2021-2022 | |
| Galderma Laboratories, L.P. | $168.33 | 2021-2023 | |
| Ermi LLC | $105.33 | 2021 | |
| Theratechnologies INC. | $19.19 | 2021 | |
| Allergan, INC. | $13.75 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rispba Mccray-Garrison listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.